AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BCAL DIAGNOSTICS LTD

0.065

-0.001-1.52%

Volume:16.79K

Turnover:1K

Market Cap:23.92M

PE:-3.26

High:0.066

Open:0.066

Low:0.065

Close:0.066

52wk High:0.155

52wk Low:0.052

Shares:368.07M

Float Shares:202.44M

Volume Ratio:0.19

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.020

EPS(LYR):-0.020

ROE:-273.29%

ROA:-48.89%

PB:-28.96

PE(LYR):-3.25

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

BCAL Diagnostics Ltd-Meet the CEO FY 2026 Results Webinar 3 Sept 2026 at 1Pm

THOMSON REUTERS

Becton Dickinson (BDX) Hits STANCE Trial Milestone, Is The Stock Fully Valued?

Simply Wall St.

Becton Dickinson Reaches 50% Enrollment in Breast Surgery Trial

MT Newswires Live

Did Stronger Sales and Quality Shuffle Just Shift Becton Dickinson's (BDX) Investment Narrative?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/BDX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BDX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","market":"AU","secType":"STK","nameCN":"BCAL DIAGNOSTICS LTD","latestPrice":0.065,"timestamp":1788230845434,"preClose":0.066,"halted":0,"volume":16785,"delay":0,"changeRate":-0.015151515151515164,"nameEN":"BCAL DIAGNOSTICS LTD","floatShares":202437334,"shares":368067640,"eps":-0.01993,"marketStatus":"Trading","change":-0.001,"latestTime":"09-01 13:26:31 AEST","open":0.066,"high":0.066,"low":0.065,"amount":1105,"amplitude":0.015152,"askPrice":0.066,"askSize":1516,"bidPrice":0.065,"bidSize":144324,"shortable":3,"etf":0,"ttmEps":-0.01993,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788242400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.066,"openAndCloseTimeList":[[1788220800000,1788242400000]],"volumeRatio":0.186794,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BDX.AU","preClose":0.066,"auctionPrice":0.066,"auctionVolume":10000,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156579082}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","floatShares":202437334,"roa":"-48.89%","roe":"-273.29%","lyrEps":-0.02,"volumeRatio":0.186794,"shares":368067640,"dividePrice":0,"high":0.066,"amplitude":0.015152,"preClose":0.066,"low":0.065,"week52Low":0.052,"pbRate":"-28.96","psRate":"9.38","week52High":0.155,"institutionHeld":0,"latestPrice":0.065,"committee":0.97921,"eps":-0.01993,"divideRate":0,"volume":16785,"delay":0,"ttmEps":-0.01993,"open":0.066,"prevYearClose":0.105,"prevWeekClose":0.066,"prevMonthClose":0.066,"prevQuarterClose":0.075,"fiveDayClose":0.052,"twentyDayClose":0.075,"sixtyDayClose":0.07,"earningDate":1788364800000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BDX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"BDX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788393600000,"name":null,"time":"","dateTimestamp":1788357600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BDX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BDX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663825024","title":"BCAL Diagnostics Ltd-Meet the CEO FY 2026 Results Webinar 3 Sept 2026 at 1Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2663825024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663825024?lang=en_us&edition=fundamental","pubTime":"2026-08-31 12:30","pubTimestamp":1788150646,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUE9N79Z8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019352","title":"Becton Dickinson (BDX) Hits STANCE Trial Milestone, Is The Stock Fully Valued?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019352","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019352?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:30","pubTimestamp":1787959830,"startTime":"0","endTime":"0","summary":"Becton Dickinson (BDX) stock is back in focus after the company reported that its STANCE clinical trial of GalaFLEX LITE Scaffold in breast revision surgery hit a first enrollment milestone, triggering a planned interim analysis.\nAgainst this backdrop, Becton Dickinson shares trade at US$189.52, with the stock posting a 30 day share price return of 12.54% and a 90 day share price return of 28.82%. The 1 year total shareholder return of 28.03% contrasts with a weaker 3 year record and points...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-hits-stance-trial-milestone-is-the-stoc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/becton-dickinson-bdx-hits-stance-trial-milestone-is-the-stoc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4585","IE00BFXG1179.USD","LU0130103400.USD","LU1894683264.USD","BDX.AU","LU0266013472.USD","LU1571399168.USD","LU1894683348.USD","BK4504","BK4082","BDX","LU1150488218.USD","LU0878866978.SGD","LU0511384066.AUD","LU1854104046.USD","LU0068578508.USD","LU1201861165.SGD","LU0433182093.SGD","LU0006061336.USD","LU1150488135.SGD","LU0985489474.SGD","LU0477156797.USD","LU0289739343.SGD","IHI","LU1059921491.USD","LU0130518102.USD","LU0985320562.USD","LU0648000940.SGD","LU1489326972.SGD","LU0289961442.SGD","LU1854103824.USD","BK4588","LU0072461881.USD","LU0162691827.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662670497","title":"Becton Dickinson Reaches 50% Enrollment in Breast Surgery Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662670497","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662670497?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:43","pubTimestamp":1787831011,"startTime":"0","endTime":"0","summary":"Becton, Dickinson and Co.  said Thursday that its clinical study evaluating GalaFLEX LITE Scaffold in breast revision surgery for capsular contracture has treated 274 patients across 33 active US states.The total number shows over 50% of planned enrollment and has triggered the first planned interim analysis, the medical technology company said.The trial evaluates the bioabsorbable device for treating capsular contracture, a complication where scar tissue hardens around implants, the company said.Shares of the company were down less than 1% in recent Thursday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0266013472.USD","LU0878866978.SGD","BK7067","LU0289739343.SGD","LU0072461881.USD","LU0162691827.USD","LU0433182093.SGD","LU1854104046.USD","LU0130103400.USD","BK4504","LU0477156797.USD","LU0130518102.USD","LU1854103824.USD","BK4082","LU1150488218.USD","LU1894683264.USD","IHI","LU1571399168.USD","LU0068578508.USD","LU1489326972.SGD","LU0289961442.SGD","LU1894683348.USD","LU1150488135.SGD","LU1201861165.SGD","BDX.AU","LU0985320562.USD","LU0511384066.AUD","LU0006061336.USD","BDX","IE00BFXG1179.USD","LU1059921491.USD","LU0648000940.SGD","BK4588","BK4585","LU0985489474.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660949476","title":"Did Stronger Sales and Quality Shuffle Just Shift Becton Dickinson's (BDX) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660949476","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660949476?lang=en_us&edition=fundamental","pubTime":"2026-08-20 05:33","pubTimestamp":1787175181,"startTime":"0","endTime":"0","summary":"Becton, Dickinson and Company recently reported third-quarter fiscal 2026 results showing higher sales of US$4,983,000,000 compared with a year earlier, while net income for both the quarter and year-to-date periods was lower than the prior year.\nAlongside these mixed earnings, BD advanced its tissue regeneration pipeline by fully enrolling the PREVENT trial for Phasix Mesh and reshaped its quality leadership team with the upcoming appointment of Gary Sorsher as chief quality officer and the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/did-stronger-sales-and-quality-shuffle-just-shift-becton-dic","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/did-stronger-sales-and-quality-shuffle-just-shift-becton-dic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BDX","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":13,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BDX.AU\",params:#limit:6,delay:true,,,undefined,":[]}}